GlassScriptPhysician profile
Rajendra P Gajula
NPI 1124011614
$30,104.63
in general payments reported to CMS, 2019-2025
22 companies · $1,965 in 2025
The $1,965 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $662 · 2021: $1,863 · 2022: $2,060 · 2023: $7,715 · 2024: $1,611 · 2025: $1,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,910 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,190 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,910.45 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,190.00 |
| Education | $190.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $11,761.78 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $7,870.75 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $2,615.56 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Neurocrine Biosciences, INC. | $1,490.23 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,295.12 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $1,028.62 | 2019-2024 | Aristada, Lybalvi, Aristada Initio |
| Sunovion Pharmaceuticals INC. | $525.59 | 2019-2021 | |
| Abbvie INC. | $518.79 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $505.51 | 2019-2025 | Fanapt, Hetlioz |
| Jazz Pharmaceuticals INC. | $470.12 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $435.05 | 2021-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $377.24 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $278.98 | 2019-2023 | Trintellix |
| Indivior INC. | $209.18 | 2019-2025 | Perseris, Sublocade |
| Allergan, INC. | $163.96 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $137.57 | 2019-2025 | Rexulti |
| Biogen, INC. | $120.00 | 2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $118.50 | 2022 | |
| Axsome Therapeutics, INC. | $116.36 | 2023 | Auvelity |
| Shire North American Group INC | $31.00 | 2019 | |
| Braeburn INC. | $18.55 | 2024 | Brixadi |
| Corium, LLC | $16.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajendra Gajula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.